Biotech Values

[Checkpoint]

Of course it is to early to tell which is the better agent, and if a few percent are significant. But I take an opposite view on the combination of Yervoy and nivolumab. This combination result is probably the most promising in all of oncology. At the end of the day if a loved on had Melanoma most people would want the combo if it was available.